Amgen and Centocor Ortho Biotech Products: FDA approves REMS for Aranesp.

Amgen and Centocor Ortho Biotech Products: FDA approves REMS for Aranesp, PROCRIT and EPOGEN ESAs Amgen Inc Hvad bør jeg undgå? . and Centocor Ortho Biotech Items, L.P., today announced that the U.S. As part of the REMS, a Medication Guideline explaining the risks and great things about ESAs must be provided to all patients receiving ESAs. To ensure continued usage of ESAs for healthcare providers who prescribe, or prescribe and dispense, ESAs to individuals with cancer, providers are required to train and enroll in the ESA APPRISE Oncology Program and to document that a discussion about the dangers of ESAs took place with each patient prior to the initiation of each new span of ESA therapy.